Stem Cell Research

To help keep our members up to date on Stem Cell research, The Stroke Network is reprinting part of a press release from Stem Cell Therapy International, Inc.

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion dollars was created to promote stem cell research. Since that time, four other states New Jersey, Connecticut, Illinois and Wisconsin, have allocated significant funds for stem cell research. For additional information on SCTI’s research and treatment programs please visit our website @ www.scticorp.com.

 About Stem Cell Therapy International (SCTI)

Stem Cell Therapy International, Inc. is engaged in the field of research and development of regenerative medicine. SCTI manufactures biological solutions that are currently being used in the treatment of patients suffering from degenerative disorders of the human body such as Alzheimer’s, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer. The Company has established agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI intends to provide these biological solutions containing stem cell products in the United States as well, to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials. Their products, which are available now, include various biological solutions containing fetal stem cells, adult stem cells and stem cell which are extracted from umbilical cord blood.

Press Release by Stem Cell Therapy International, Inc. Dec 14, 2005. Reprinted with permission.